NEW YORK, — Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of American Renal Associates Holdings, Inc. (NYSE: ARA) resulting from allegations that American Renal may have issued materially misleading business information to the investing public.
On March 8, 2019, American Renal announced it would delay the filing of its earnings report for the fiscal year ended December 31, 2018 as it continues to examine reserve computations and other accounting practices that may have an impact on the company’s accounts receivable and revenue for fiscal year 2018, as well as previously reported fiscal years ranging from 2014 through 2017. This follows the Securities and Exchange Commission’s (“SEC”) October 2018 request for documents concerning American Renal’s revenue recognition, collections, and other related matters. On this news, shares of American Renal fell $2.05 per share or over 16% to close at $10.46 per share on March 8, 2019.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by American Renal investors. If you purchased shares of American Renal, please visit the firm’s website at https://www.rosenlegal.com/cases-register-1533.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.
Attorney Advertising. Prior results do not guarantee a similar outcome.